Teva Found on Summary Judgment to Infringe Mylan Patent for Perforomist® Inhalation Solution
PITTSBURGH, July 18, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that the United States District Court for the Northern District of West Virginia has granted Mylan's motion for partial summary judgment finding that the production and marketing of Teva's generic version of Mylan's Perforomist® Inhalation Solution infringes one of Mylan's Orange Book listed patents (U.S. Patent No. 6,667,344) on Perforomist. Teva's abbreviated new drug application (ANDA) for a generic Perforomist has not yet been granted tentative or final approval by the U.S. Food and Drug Administration.
Trial on the remaining issues in the case is currently scheduled to begin later this month.
This press release includes statements that constitute "forward-looking statements," including with regard to litigation. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: strategies by competitors or other third parties to delay or prevent product sales; risks inherent in legal and regulatory processes; and the other risks detailed in the company's periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com
SOURCE Mylan Inc.
CONTACT: Nina Devlin (Media), 724.514.1968; Kris King (Investors), 724.514.1813
Web Site: http://www.mylan.com